Patents Assigned to Immuno Japan Inc.
  • Non-A non-B hepatitis related nucleic acids proteins peptides antigens and antibodies
    Patent number: 6103485
    Abstract: Novel nucleic acids, proteins, peptides, antigens, and antibodies related to non-A, non-B hepatitis, and non-A, non-B hepatitis diagnostic reagents using those materials.
    Type: Grant
    Filed: May 20, 1998
    Date of Patent: August 15, 2000
    Assignee: Immuno Japan Inc.
    Inventors: Shunji Mishiro, Tetsuo Nakamura
  • Oligonucleotide primers, and their application for high-fidelity detection of non-A, non-B hepatitis virus
    Patent number: 5856458
    Abstract: The noncoding region, containing at least 324 nucleotides, of the 5' terminus of non-A, non-B hepatitis virus is disclosed. Also disclosed is the nucleotide sequence of the structural gene which is upstream of the noncoding region. Oligonucleotide primers derived from these regions can be used to to detect non-A, non-B hepatitis virus.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 5, 1999
    Assignee: Immuno Japan Inc.
    Inventors: Hiroaki Okamoto, Tetsuo Nakamura
  • Non-A, non-B hepatitis related nucleic acids, proteins, peptides, antigens, and antibodies
    Patent number: 5766867
    Abstract: Novel nucleic acids, proteins, peptides, antigens, and antibodies related to non-A, non-B hepatitis, and non-A, non-B hepatitis diagnostic reagents using those materials.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: June 16, 1998
    Assignee: Immuno Japan Inc.
    Inventors: Shunji Mishiro, Tetsuo Nakamura
  • Formulated medicine for treatment and prevention of opportunistic infectious diseases complicated by infection with lentivirus
    Patent number: 5576299
    Abstract: The protein lactoferrin can be used both for treating and/or preventing of portunistic infections frequently complicating Immunodeficiency Virus positive animals including human beings. The protein greatly improves the quality of life in such immunodeficiency virus infected animals. The dosage of the protein is usually 0.1-100 mg/kg daily, and preferably 0.5-50 mg/kg.
    Type: Grant
    Filed: March 2, 1993
    Date of Patent: November 19, 1996
    Assignee: Immuno Japan, Inc.
    Inventors: Kunio Ando, Junichi Kishimoto
  • Oligonucleotides of HCV, primers and probes therefrom, method of determining HCV genotypes and method of detecting HCV in samples
    Patent number: 5550016
    Abstract: Disclosed are nucleotide sequences of the 5' noncoding region and the following structural protein coding region of HCV which have not been previously discovered, and a method to detect HCV with high specificity and good sensitivity using the oligonucleotides as a primer or a probe in order to detect extensively HCV genes of more varied strains.
    Type: Grant
    Filed: November 24, 1993
    Date of Patent: August 27, 1996
    Assignee: Immuno Japan Inc.
    Inventor: Hiroaki Okamoto
  • Oligonucleotides and determination system of HCV genotypes
    Patent number: 5427909
    Abstract: Hepatitis C virus oligonucleotides and a system to determine hepatitis C virus genotypes with polymerase chain reaction utilizing those oligonucleotides as primers.
    Type: Grant
    Filed: September 8, 1992
    Date of Patent: June 27, 1995
    Assignee: Immuno Japan Inc.
    Inventors: Hiroaki Okamoto, Tetsuo Nakamura
  • Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
    Patent number: 5428145
    Abstract: Non-A, non-B hepatitis (NANB hepatitis) virus RNA and its corresponding polypeptide, related antigen, antibody, and detection systems for detecting NANB hepatitis antigen or antibodies.
    Type: Grant
    Filed: August 7, 1992
    Date of Patent: June 27, 1995
    Assignee: Immuno Japan, Inc.
    Inventors: Hiroaki Okamoto, Tetsuo Nakamura
  • Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
    Patent number: 5198419
    Abstract: Lactoferrin can be used to increase the efficacy of beta-lactam antibiotics. There is a potentiating effect when lactoferrin is administered either simultaneous with or shortly before or after the administration of beta-lactam antibiotics. The dosage of lactoferrin administered is usually 0.5-100 mg/kg and preferably 1-10 mg/kg.
    Type: Grant
    Filed: October 4, 1991
    Date of Patent: March 30, 1993
    Assignee: Immuno Japan Inc.
    Inventors: Kunio Ando, Sachiko Goto
  • Non-A, Non-B hepatitis virus genome RNA, cDNA and virus antigen protein
    Patent number: 5176994
    Abstract: Non-A, Non-B Hepatitis Virus Genome RNA is disclosed along with cDNA and Virus Antigen Protein.
    Type: Grant
    Filed: May 15, 1991
    Date of Patent: January 5, 1993
    Assignee: Immuno Japan Inc.
    Inventors: Shunji Mishiro, Tetsuo Nakamura
  • Analgesic and anti-inflammatory medicine
    Patent number: 5128334
    Abstract: A composition containing ascorbic acid and/or its derivatives and aspirin and/or its derivatives is an effective analgesic and anti-inflammatory medicine. A method for reducing the side effects of aspirin in a mammal involves the administration of an effective amount of a pharmaceutical composition comprising ascorbic acid and/or its derivatives and aspirin/or its derivatives.
    Type: Grant
    Filed: December 21, 1990
    Date of Patent: July 7, 1992
    Assignee: Immuno Japan Inc.
    Inventors: Yoshiyuki Nishikawa, Tetsuo Nakamura
  • Non-A, Non-B hepatitis virus genome RNA, cDNA and virus antigen protein
    Patent number: 5077193
    Abstract: Non-A, Non-B hepatitis virus genome RNA is disclosed along with cDNA and virus antigen protein.
    Type: Grant
    Filed: June 19, 1990
    Date of Patent: December 31, 1991
    Assignee: Immuno Japan Inc.
    Inventors: Shunji Mishiro, Tetsuo Nakamura